MicroPort NaviBot and MicroPort Orthopedics announced the first clinical use of the SkyWalker™ Robotic System in the US.
SkyWalker provides information that can help the surgeon achieve the desired joint line reconstruction while providing data to optimally balance soft tissues. Combined with MicroPort’s Evolution® Medial-Pivot Knee System, the system replicates the natural stability and motion of the knee delivering a functionally restorative design that offers surgeons an innovative solution to problems such as instability, anterior knee pain and functional limitations.
The organization has now moved into its limited market release and intends to ramp up its site locations. MicroPort MedBot also intends to integrate new applications on its platform, including hip replacement as a next application in early 2024.
Jake Adams, VP, Commercial Operations, said, “We believe this pairing will be an attractive clinical solution when compared to current options on the market – defining a new, ‘patient first’ standard for treatment while improving the overall knee surgical experience.”
MicroPort NaviBot and MicroPort Orthopedics announced the first clinical use of the SkyWalker™ Robotic System in the US.
SkyWalker provides information that can help the surgeon achieve the desired joint line reconstruction while providing data to optimally balance soft tissues. Combined with MicroPort's Evolution® Medial-Pivot Knee System,...
MicroPort NaviBot and MicroPort Orthopedics announced the first clinical use of the SkyWalker™ Robotic System in the US.
SkyWalker provides information that can help the surgeon achieve the desired joint line reconstruction while providing data to optimally balance soft tissues. Combined with MicroPort’s Evolution® Medial-Pivot Knee System, the system replicates the natural stability and motion of the knee delivering a functionally restorative design that offers surgeons an innovative solution to problems such as instability, anterior knee pain and functional limitations.
The organization has now moved into its limited market release and intends to ramp up its site locations. MicroPort MedBot also intends to integrate new applications on its platform, including hip replacement as a next application in early 2024.
Jake Adams, VP, Commercial Operations, said, “We believe this pairing will be an attractive clinical solution when compared to current options on the market – defining a new, ‘patient first’ standard for treatment while improving the overall knee surgical experience.”
Copy to clipboard 
